Iovance Biotherapeutics, Inc. (IOVA)
8.56
+0.42
(+5.16%)
USD |
NASDAQ |
Sep 11, 15:43
Iovance Biotherapeutics Gross Profit (TTM) : 120.66M for June 30, 2026
Gross Profit (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 120.66M |
| March 31, 2026 | 71.49M |
| December 31, 2025 | 45.02M |
| September 30, 2025 | 32.95M |
| June 30, 2025 | 26.10M |
| March 31, 2025 | 23.42M |
| December 31, 2024 | 17.67M |
| September 30, 2024 | -17.94M |
| June 30, 2024 | -40.80M |
| March 31, 2024 | -42.88M |
| December 31, 2023 | -36.75M |
| September 30, 2023 | -28.86M |
| June 30, 2023 | -24.33M |
| March 31, 2023 | -21.81M |
| December 31, 2022 | -21.09M |
| September 30, 2022 | -19.97M |
| June 30, 2022 | -21.02M |
| March 31, 2022 | -16.30M |
| December 31, 2021 | -13.98M |
| September 30, 2021 | -12.29M |
| June 30, 2021 | -8.017M |
| March 31, 2021 | -9.247M |
| December 31, 2020 | -8.712M |
| September 30, 2020 | -8.101M |
| June 30, 2020 | -8.372M |
| Date | Value |
|---|---|
| March 31, 2020 | -8.55M |
| December 31, 2019 | -8.123M |
| September 30, 2019 | -6.092M |
| June 30, 2019 | -4.094M |
| March 31, 2019 | -2.423M |
| December 31, 2018 | -0.956M |
| September 30, 2018 | -0.946M |
| June 30, 2018 | -0.941M |
| March 31, 2018 | -0.959M |
| December 31, 2017 | -0.952M |
| September 30, 2017 | -1.00M |
| June 30, 2017 | -0.902M |
| March 31, 2017 | -0.93M |
| December 31, 2016 | -0.978M |
| September 30, 2016 | -0.996M |
| June 30, 2016 | -1.114M |
| March 31, 2016 | -1.083M |
| December 31, 2015 | -0.9996M |
| September 30, 2015 | -0.7571M |
| June 30, 2015 | -0.4961M |
| March 31, 2015 | -0.2571M |
| December 31, 2014 | -0.0882M |
| September 30, 2014 | -0.025M |
| June 30, 2014 | -6.720M |
| March 31, 2014 | -6.720M |
Gross Profit Definition
Annual, Interim and Preliminary Items - Commercial, Other Financial Companies
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit (TTM) Benchmarks
| Amgen, Inc. | 27.78B |
| AVITA Medical, Inc. | 61.68M |
| Halozyme Therapeutics, Inc. | 1.271B |
| Neurocrine Biosciences, Inc. | 3.289B |
| Editas Medicine, Inc. | 44.58M |